What is the AZD-1222 coronavirus disease 2019 (COVID-19) vaccine?
AZD-1222 (ChAdOx1 nCoV-19; AstraZeneca) COVID-19 vaccine is derived from viral vector method of technology. AZD-1222 (ChAdOx1 nCoV-19; AstraZeneca) COVID-19 vaccine contains surface glycoprotein antigen gene. Dose series = 1 dose given as half, both half doses have difference of 8-12 weeks Vaccine efficacy = 63.09% Safety concerns = none